Doxazosin Tablet
Product Images NDC 68071-3341

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 68071-3341). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 3341 6

Doxazosin 2 mg tablets label from NuCare Pharmaceuticals, Inc. The label indicates a 60-count package with each tablet containing 2 mg Doxazosin Mesylate. The tablets are described as capsule-shaped, white to off-white, and scored with imprint 'APO' on one side and '094' on the other. The label includes barcode, lot number, expiration date placeholders, and storage instructions to keep at controlled temperature 68-77°F. The product is prescription only.*

FDA Label Image

Doxazosin-structure.jpg (Doxazosin Structure)

Chemical structure diagram of doxazosin, showing its molecular configuration with distinct rings and functional groups, consistent with the active ingredient of doxazosin tablets.*

FDA Label Image

Figure1.jpg (Figure1)

Two line graphs show clinical data for Doxazosin 2 mg tablets versus placebo over 14 weeks. The left graph depicts mean change in total symptom score from baseline, showing greater symptom score improvement with Doxazosin compared to placebo. The right graph illustrates mean increase in maximum urinary flow rate (mL/sec) from baseline, with Doxazosin showing a higher increase than placebo. Both charts include error bars and statistical significance markers.*

FDA Label Image

Table3.jpg (Table3)

A data table outlining the summary of effectiveness data from placebo-controlled trials for Doxazosin. The table compares symptom scores and maximum flow rate changes in three studies at various doses versus placebo, showing mean baseline values and mean changes. A bar graph adjacent to the table visually represents maximum flow rate and symptom score changes for Study 2 at placebo and Doxazosin 4 mg and 8 mg doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.